94 Result(s)

Article

Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

Alissa Visram, Celine Vachon, Linda B. Baughn, Dirk Larson, James Smadbeck… in Leukemia (2024)

Article

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Nadine Abdallah, David Murray, Angela Dispenzieri, Prashant Kapoor… in Leukemia (2024)

Article

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Ghulam Rehman Mohyuddin, Samuel M. Rubinstein, Shaji Kumar… in Blood Cancer Journal (2024)

Article

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Saurabh Zanwar, Morie A. Gertz, Eli Muchtar, Francis K. Buadi… in Leukemia (2024)

Article

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multipl...

Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam… in BMC Cancer (2024)

Article

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune systems and might be at increased risk for severe COVID-19 outcomes. This study charac...

Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder… in Blood Cancer Journal (2023)

Article

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies

Susan Bal, Noel Estrada-Merly, Luciano J. Costa… in Blood Cancer Journal (2023)

Article

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748

Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle… in Leukemia (2023)

Article

Relationship among three common hematological premalignant conditions

Nicholas J. Boddicker, Sameer A. Parikh, Aaron D. Norman, Kari G. Rabe… in Leukemia (2023)

Article

Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance

Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia...

Alexander J. Ryu, Shaji Kumar, Angela Dispenzieri, Robert A. Kyle… in Blood Cancer Journal (2023)

Article

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma

Multiple Myeloma patients eligible for autologous hematopoietic transplantation (AHT) typically receive 3–6 cycles of induction therapy before transplant. The last induction cycle is completed 2–4 weeks prior ...

Charalampos Charalampous, Utkarsh Goel, Morie Gertz… in Bone Marrow Transplantation (2023)

Article

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy

Saurabh Zanwar, Matthew Ho, Francis K. Buadi, Sikander Ailawadhi… in Blood Cancer Journal (2022)

Article

Smoldering multiple myeloma current treatment algorithms

Smoldering multiple myeloma (SMM) is an asymptomatic condition that occupies a space between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum of clonal pla...

S. Vincent Rajkumar, Shaji Kumar, Sagar Lonial… in Blood Cancer Journal (2022)

Article

Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis

Thierry Facon, Jesús San-Miguel, Meletios A. Dimopoulos… in Advances in Therapy (2022)

Article

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms

Marie-France Gagnon, Shulan Tian, Susan Geyer, Neeraj Sharma… in Blood Cancer Journal (2022)

Article

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

We herein present an overview of the upcoming 5^th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be pres...

Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle… in Leukemia (2022)

Article

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments ar...

Shaji Kumar, Lawrence Baizer, Natalie S. Callander… in Blood Cancer Journal (2022)

Article

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even w...

Jean-Sébastien Claveau, Francis K. Buadi, Shaji Kumar in Oncology and Therapy (2022)

Article

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Nadine Abdallah, David Murray, Angela Dispenzieri, Prashant Kapoor… in Leukemia (2022)